Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
نویسندگان
چکیده
منابع مشابه
Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension.
therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 6: 745–753. 4 de Gracia J, Morell F, Bofill JM, Rodrigo MJ, Cosculluela C. Impaired lung function in patients with IgA deficiency and low levels of IgG2 or IgG3. N Engl J Med 1986; 314: 925–926. 5 de Gracia J, Miravitlles M, Vendrell M, Rodrigo MJ, Codina R, Morell F. Study of the IgG sub...
متن کاملEfficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
UNLABELLED (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/Introduction: To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months' therapy. MATERIALS AND METHODS A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, a...
متن کاملDual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
BACKGROUND Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH. METHODS We retrospectively analyzed 7 consecut...
متن کاملClinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and treatment of hypertension continues to be a challenge. Guidelines recommend that many patients will require two or more antihypertensive agents from different classes. Combining an angiotensin II receptor blocker (ARB) with hydrochlorothi...
متن کاملGoal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Combination therapy may improve outcome in patients with severe pulmonary arterial hypertension (PAH). PAH patients were treated according to a goal-oriented therapeutic strategy. Patients who did not reach the treatment goals with monotherapy received combination treatment according to a predefined strategy, including bosentan, sildenafil and inhaled iloprost. Intravenous iloprost and lung tra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Reports
سال: 2019
ISSN: 2434-0790
DOI: 10.1253/circrep.cr-19-0029